Table 1:
TOF (n = 41) | Control (n = 15) | P-value | |
---|---|---|---|
Age (years) | 14 (10–21) | 10 (10–18) | 0.61 |
Female gender, n (%) | 19 (46) | 9 (60) | 0.37 |
BSA (m2) | 1.28 ± 0.43 | 1.26 ± 0.32 | 0.66 |
LV-EDVi (ml/m2) | 84 (71–95) | 76 (71–83) | 0.34 |
LV-ESVi (ml/m2) | 38 (32–45) | 32 (31– 5) | 0.032 |
LV-SVi (ml) | 46 (38–52) | 43 (41–57) | 0.08 |
LV-EF (%) | 55 (52–57) | 58 (55–62) | 0.023 |
LV-CI (l/min/m2) | 3.3 (2.8–3.8) | 3.7 (3.4–3.9) | 0.123 |
RV-EDVi (m/s) | 135 (113–154) | 76 (73–96) | <0.001 |
RV-ESVi | 67 (56–80) | 34 (32–36) | <0.001 |
RV-EF | 49 (45–55) | 57 (56–62) | <0.001 |
Data are represented as median with corresponding interquartile range or mean ± standard deviation.
BSA: body surface area; CI: cardiac index; EDVi: end-diastolic volume index; EF: ejection fraction; ESVi: end-systolic volume index; LV: left ventricle; MRI: magnetic resonance imaging; RV: right ventricle; SV: stroke volume; TOF: tetralogy of Fallot.